Single-center experience with tacrolimus-based immunosuppressive regimens in renal transplantation

Molecular Immunology

Volumn 39, Issue 17-18, 2003, Pages 1067-1072

  Abou Jaoude, Maroun M ^a   Almawi, Wassim Y ^b  

^a SAINT GEORGE HOSPITAL UNIVERSITY MEDICAL CENTER   (Lebanon)

^b ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

Acute rejection; Renal transplantation; Tacrolimus

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; BACTERIAL INFECTION; BIOPSY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; EXPERIENCE; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MALE; MICROEMULSION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); CUCUMBER MOSAIC VIRUS;

EID: 0038094499     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(03)00076-2     Document Type: Conference Paper

References (36)

1. Almawi W.Y., Melemedjian O.K. Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A. Nephrol. Dial. Transplant. 15:2000;1916-1918.
2. Almawi W.Y., Assi J.W., Chudzik D.M., Abou-Jaoude M.M., Rieder M.J. Inhibition of cytokine production and cytokine-stimulated T-cell activation by FK506 (tacrolimus). Cell Transplant. 10:2001;615-623.
3. Boots J.M., van Duijnhoven E.M., Christiaans M.H., Nieman F.H., van Suylen R.J., van Hooff J.P. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transpl. Int. 14:2001;370-383.
4. Busque S., Demers P., St-Louis G., Boily J.G., Tousignant J., Lemieux F., Smeesters C., Corman J., Daloze P. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. Transplant. Proc. 30:1998;1247-1248.
5. Cacciarelli T.V., Reyes J., Jaffe R., Mazariegos G.V., Jain A., Fung J.J., Green M. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr. Transplant. 5:2001;359-364.
6. European Tacrolimus Multicenter Renal Study Group, 1997. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 64, 436-443.
7. Friemann S., Feuring E., Padberg W., Ernst W. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant. Proc. 30:1998;1240-1242.
8. Ghasemian S.R., Light J.A., Currier C., Sasaki T.M., Aquino A. Tacrolimus vs. Neoral in renal and renal/pancreas transplantation. Clin. Transplant. 13:1999;123-125.
9. Gruessner R.W., Burke G.W., Stratta R., Sollinger H., Benedetti E., Marsh C., Stock P., Boudreaux J.P., Martin M., Drangstveit M.B., Sutherland D., Gruessner A. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation. 61:1996;261-273.
10. Hiraoka A., Ohashi Y., Okamoto S., Moriyama Y., Nagao T., Kodera Y., Kanamaru A., Dohy H., Masaoka T. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 28:2001;181-185.
11. Jensik S.C. Tacrolimus in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK506 Kidney Transplant Study Group. Transplant. Proc. 30:1998;1216-1218.
12. Katari S.R., Magnone M., Shapiro R., Jordan M., Scantlebury V., Vivas C., Gritsch H.A., McCauley J., Starzl T., Demetris A.J., Randhawa P.S. Tacrolimus nephrotoxicity after renal transplantation. Transplant. Proc. 29:1997;311.
13. Kintmalm G.B., Goldstein R., Gonwa T., Wiesner R.H., Krom R.A., Stratta B.B.R., Ascher N.L., Roberts J.W., Lake J. Use of Prograf (FK506) as rescue therapy for refractory rejection after liver transplantation. Transplant. Proc. 25:1993;679.
14. Kliem V., Peterson R., Ehlerding G., Schaunann D., Eisenberger U., Koch K.M., Pichlmayr R., Brunkhorst R. Tacrolimus for steroid and OKT3-resistant rejection in kidney recipients. Transplant. Proc. 30:1998;1251-1253.
15. Knoll G.A., Bell R. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomized trials. Br. Med. J. 318:1999;1104-1107.
16. Kobashigawa J.A., Kasiske B.L. Hyperlipidemia in solid organ transplantation. Transplantation. 63:1997;331-338.
17. McCauley J., Shapiro R., Bronster O., Jordan M., Ellis D., Gilboa N., Scantlibury V., Jensen C., Jain A., Starzl T. Renal transplantation under FK506 in patients with previous loss renal function due to hemolytic uremic syndrome. Transplant. Proc. 23:1991;3068-3070.
18. McCune T.R., Thacker L.R. II, Peters T.G., Mulloy L., Rohr M.S., Adams P., Yium J., Light J.A., Pruett T., Gaber A.O., Selman S.H., Jonsson J., Hayes J.M., Wright F.H., Armata T., Blanton J., Burdick J.F. Effects of tacrolimus on hyperlipidemia after successful renal transplantation. A Southeastern Organ Procurement Foundation Multicenter Clinical Study. Transplantation. 65:1998;87-92.
19. McMaster P. Patient and graft survival in the European Multicentre Liver Study - FK506 vs. cyclosporin A. Transpl. Int. 7(Suppl. 1):1994;S32-S36.
20. Meiser B.M., Uberfuhr P., Fuchs A., Schulze C., Nollert G., Mair H., Martin S., Pfeiffer M., Reichenspurner H., Kreuzer E., Reichart B. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. J. Heart Lung Transplant. 16:1997;795-800.
21. Moxey-Mims M.M. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506). Transplantation. 68:1999;320.
22. Pascual J., Ortuno J. Simple tacrolimus-based immunosuppressive regimens following renal transplantation: a large multicenter comparison between double and triple therapy. Transplant. Proc. 34:2002;89-91.
23. Plosker G.L., Foster R.H. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs. 59:2000;323-389.
24. Schroeder T.J., Weiss M.A., Smith R.D., Stephens G.W., First M.R. The efficacy of OKT3 in vascular rejection. Transplantation. 51:1991;312-315.
25. Shapiro R. Tacrolimus in pediatric renal transplantation: a review. Pediatr. Transplant. 2:1998;270-276.
26. Shapiro R., Jordan M., Fung J., McCauley J., Johnston J., Iwaki Y., Tzakis A., Hakala T., Todo S., Starzl T.E. Kidney transplantation under FK506 immunosuppression. Transplant. Proc. 23:1991;920-923.
27. Shapiro R., Scantlebury V.P., Jordan M.L., Vivas C., Tzakis A.G., Ellis D., Gilboa N., Hopp L., McCauley J., Irish W. FK506 in pediatric kidney transplantation - primary and rescue experience. Pediatr. Nephrol. 9:1995;S43-S48.
28. Shapiro R., Jordan M.L., Scantlebury V.P., Vivas C., Gritsch H.A., McCauley J., McQuitty D., Randhawa P., Irish W., McMichael J., Hakala T.R., Simmons R.L., Fung J.J., Starzl T.E. Outcome after steroid withdrawal in renal transplantation patients receiving tacrolimus-based immunosuppression. Transplant. Proc. 30:1998;1375-1377.
29. Shapiro R., Scantlebury V.P., Jordan M.L., Vivas C., Ellis D., Lombardozzi-Lane S., Gilboa N., Gritsch H.A., Irish W., McCauley J., Fung J.J., Hakala T.R., Simmons R.L., Starzl T.E. Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation. 67:1999;299-303.
30. Spencer C.M., Goa K.L., Gillis J.C. Tacrolimus. Drugs. 54:1997;925-975.
31. Starzl T., Fung J., Jordan M., Shapiro R., Tzakis A., McCauley J., Johnston J., Iwaki Y., Jain A., Alessiani M. Kidney transplantation under FK506. J. Am. Med. Assoc. 264:1990;63-67.
32. Treede H., Klepetko W., Reichenspurner H., Zuckermann A., Meiser B., Birsan T., Wisser W., Reichert B. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J. Heart Lung Transplant. 20:2001;511-517.
33. Vincenti F., Laskow D.A., Neylan J.F., Mendez R., Matas A.J. One-year follow-up of an open label trial of FK506 for primary kidney transplantation: a report of the US Multicenter FK506 Kidney Transplant Group. Transplantation. 61:1996;1576-1581.
34. Woodle E.S., Thistlethwaite J.R., Gordon J.H., Laskow D., Deierhoi M.H., Burdick J., Pirsch J.D., Sollinger H., Vincenti F., Burrows L., Schwartz B., Danovitch G.M., Wilkinson A.H., Shaffer D., Simpson M.A., Freeman R.B., Rohrer R.J., Mendez R., Aswad S., Munn S.R., Wiesner R.H., Delmonico F.L., Neylan J., Whelchel J. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. Transplantation. 62:1996;594-599.
35. Woodle E.S., Buell J., Siegel C., Kulkarni S., Kopelan A., Grewal H.P. Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: the Chicago experience. Transplant. Proc. 31:1999;84S-85S.
36. Yamauchi A., Ieiri I., Kataoka Y., Tanabe M., Nishizaki T., Oishi R., Higuchi S., Otsubo K., Sugimachi K. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation. 74:2002;571-572.